Endovascular Treatment of Erectile Dysfunction

Percutaneous Endovascular Approach for the Treatment of Arteriogenic Erectile Dysfunction
  • Jonathan D. Paul
  • Jason H. Rogers
  • Atman P. Shah
  • Sandeep Nathan


Erectile dysfunction (ED) refers to the persistent inability to achieve and maintain an erection adequate for sexual intercourse with a global prevalence in excess of 150 million and, left untreated, is widely recognized to decrease quality of life. Over one half of US males between the ages of 40 and 70 years report some degree of ED with the prevalence increasing with age and with the presence of cardiovascular risk factors such as smoking, diabetes mellitus, hyperlipidemia, and hypertension. ED may have numerous etiologies and its occurrence is often multifactorial with vasculogenic, hormonal, and emotional/psychological factors all contributing. As noted above, patients with ED frequently have cardiovascular risk factors or manifest cardiovascular disease, and indeed, many commonly prescribed pharmacotherapies for hypertension, heart disease, etc. can also promote ED. Prior pelvic trauma and central or peripheral neurologic disease may also be contributory. Despite the myriad factors listed however most ED ultimately is linked to a disorder of vascular structure or function and may relate to inadequate arterial flow, impaired cavernosal smooth muscle relaxation, or veno-occlusive dysfunction. It should be noted that given the coexistence of various contributory disease processes, evaluation and therapy for ED necessitate the coordinated, multidisciplinary efforts of urologists, vascular and sexual medicine specialists, and primary care physicians.


Erectile Dysfunction Erectile Function Internal Iliac Artery Peak Systolic Velocity Arterial Inflow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA. 1993;270:83–90.Google Scholar
  2. 2.
    Smith KJ, Roberts MS. The cost-effectiveness of sildenafil. Ann Intern Med. 2000;132:933–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Willke RJ, Yen W, Parkerson Jr GR, Linet OI, Erder MH, Glick HA. Quality of life effects of alprostadil therapy for erectile dysfunction: results of a trial in Europe and South Africa. Int J Impot Res. 1998;10:239–46.PubMedCrossRefGoogle Scholar
  4. 4.
    Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.PubMedGoogle Scholar
  5. 5.
    McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res. 2000;12 Suppl 4:S6–11.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosen RC, Cappelleri JC, Gendrano 3rd N. The International Index of Erectile Function (IIEF): a state-of-the-science review. Int J Impot Res. 2002;14:226–44.PubMedCrossRefGoogle Scholar
  7. 7.
    Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Gazzaruso C, Giordanetti S, De Amici E, Bertone G, Falcone C, Geroldi D, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation. 2004;110:22–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Rosen MP, Greenfield AJ, Walker TG, Grant P, Dubrow J, Bettmann MA, et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol. 1991;145:759–63.PubMedGoogle Scholar
  10. 10.
    El-Sakka AI, Morsy AM, Fagih BI, Nassar AH. Coronary artery risk factors in patients with erectile dysfunction. J Urol. 2004;172:251–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Campbell HE. Clinical monograph for drug formulary review: ­erectile dysfunction agents. J Manag Care Pharm. 2005;11:151–71.PubMedGoogle Scholar
  12. 12.
    Hatzichristou D, Goldstein I. Penile microvascular arterial bypass: indications and surgical considerations. Surg Annu. 1993;25(Pt 2):207–29.PubMedGoogle Scholar
  13. 13.
    Bookstein JJ, Valji K, Parsons L, Kessler W. Pharmacoarteriography in the evaluation of impotence. J Urol. 1987;137:333–7.PubMedGoogle Scholar
  14. 14.
    Mueller SC, von Wallenberg-Pachaly H, Voges GE, Schild HH. Comparison of selective internal iliac pharmaco-angiography, penile brachial index and duplex sonography with pulsed Doppler analysis for the evaluation of vasculogenic (arteriogenic) impotence. J Urol. 1990;143:928–32.PubMedGoogle Scholar
  15. 15.
    Rosen MP, Greenfield AJ, Walker TG, Grant P, Guben JK, Dubrow J, et al. Arteriogenic impotence: findings in 195 impotent men examined with selective internal pudendal angiography. Young Investigator’s Award. Radiology. 1990;174:1043–8.PubMedGoogle Scholar
  16. 16.
    Rogers JH, Karimi H, Kao J, Link D, Javidan J, Yamasaki DS, et al. Internal pudendal artery stenoses and erectile dysfunction: correlation with angiographic coronary artery disease. Catheter Cardiovasc Interv. 2010;76:882–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Bradley WE, Timm GW, Gallagher JM, Johnson BK. New method for continuous measurement of nocturnal penile tumescence and rigidity. Urology. 1985;26:4–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Uflacker R et al. Arteries of the pelvis. In: Uflacker R, editor. Atlas of vascular anatomy: an angiographic approach. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 655–98.Google Scholar
  19. 19.
    Yamaki K, Saga T, Doi Y, Aida K, Yoshizuka M. A statistical study of the branching of the human internal iliac artery. Kurume Med J. 1998;45:333–40.PubMedCrossRefGoogle Scholar
  20. 20.
    Zorgniotti AW. Practical diagnostic screening for impotence. Urology. 1984;23:98–102.PubMedCrossRefGoogle Scholar
  21. 21.
    Kaufman JM, Borges FD, Fitch 3rd WP, Geller RA, Gruber MB, Hubbard JG, et al. Evaluation of erectile dysfunction by dynamic infusion cavernosometry and cavernosography (DICC). Multi-institutional study. Urology. 1993;41:445–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Kropman RF, Schipper J, van Oostayen JA, Lycklama a Nijeholt AA, Meinhardt W. The value of increased end diastolic velocity during penile duplex sonography in relation to pathological venous leakage in erectile dysfunction. J Urol. 1992;148:314–7.PubMedGoogle Scholar
  23. 23.
    Lue TF, Hricak H, Marich KW, Tanagho EA. Evaluation of arteriogenic impotence with intracorporeal injection of papaverine and the duplex ultrasound scanner. Semin Urol. 1985;3:43–8.PubMedGoogle Scholar
  24. 24.
    Patel U, Amin Z, Friedman E, Vale J, Kirby RW, Lees WR. Colour flow and spectral Doppler imaging after papaverine-induced penile erection in 220 impotent men: study of temporal patterns and the importance of repeated sampling, velocity asymmetry and vascular anomalies. Clin Radiol. 1993;48:18–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Valji K, Bookstein JJ. Diagnosis of arteriogenic impotence: efficacy of duplex sonography as a screening tool. Am J Roentgenol. 1993;160:65–9.CrossRefGoogle Scholar
  26. 26.
    Forsberg L, Ekelund L, Hederstrom E, Olsson AM. Pharmacoangiography of the penile arteries. Urol Radiol. 1988;10:132–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Gray RR, Keresteci AG, St Louis EL, Grosman H, Jewett MA, Rankin JT, et al. Investigation of impotence by internal pudendal angiography: experience with 73 cases. Radiology. 1982;144:773–80.PubMedGoogle Scholar
  28. 28.
    Rosen MP, Walker TG, Greenfield AJ. Arteriography and radiology of impotence. Urol Radiol. 1988;10:136–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Rogers JH, Goldstein I, Kandzari DE, Kohler TS, Stinis CT, Wagner PJ, Popma JJ, Jaff MR, Rocha-Singh KJ. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012;60(25):2618–27. Accessed online at on 1 Dec 2012.Google Scholar
  30. 30.
    Castaneda-Zuniga WR, Smith A, Kaye K, Rusnak B, Herrerra M, Miller R, et al. Transluminal angioplasty for treatment of vasculogenic impotence. Am J Roentgenol. 1982;139:371–3.CrossRefGoogle Scholar
  31. 31.
    Van Unnik JG, Marsman JW. Impotence due to the external iliac steal syndrome treated by percutaneous transluminal angioplasty. J Urol. 1984;131:544–5.PubMedGoogle Scholar
  32. 32.
    Goldwasser B, Carson 3rd CC, Braun SD, McCann RL. Impotence due to the pelvic steal syndrome: treatment by iliac transluminal angioplasty. J Urol. 1985;133:860–1.PubMedGoogle Scholar
  33. 33.
    Becker GJ, Rowe DM, Holden RW, Dalsing MC, Bendick PJ. Percutaneous transluminal angioplasty for vasculogenic impotence. Indiana Med. 1986;79:256–62.PubMedGoogle Scholar
  34. 34.
    Angelini P, Fighali S. Early experience with balloon angioplasty of internal iliac arteries for vasculogenic impotence. Cathet Cardiovasc Diagn. 1987;13:107–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Valji K, Bookstein JJ. Transluminal angioplasty in the treatment of arteriogenic impotence. Cardiovasc Intervent Radiol. 1988;11:245–52.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Jonathan D. Paul
    • 1
  • Jason H. Rogers
    • 2
  • Atman P. Shah
    • 1
  • Sandeep Nathan
    • 1
  1. 1.Section of CardiologyUniversity of Chicago MedicineChicagoUSA
  2. 2.Division of Cardiovascular MedicineUniversity of California Davis Medical CenterSacramentoUSA

Personalised recommendations